AU766767B2 - Modified C1 esterase inhibitor for blocking the infectiousness of HIV - Google Patents
Modified C1 esterase inhibitor for blocking the infectiousness of HIV Download PDFInfo
- Publication number
- AU766767B2 AU766767B2 AU36865/99A AU3686599A AU766767B2 AU 766767 B2 AU766767 B2 AU 766767B2 AU 36865/99 A AU36865/99 A AU 36865/99A AU 3686599 A AU3686599 A AU 3686599A AU 766767 B2 AU766767 B2 AU 766767B2
- Authority
- AU
- Australia
- Prior art keywords
- hiv
- modified
- inhibitor
- esterase inhibitor
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940009550 c1 esterase inhibitor Drugs 0.000 title claims description 20
- 230000000903 blocking effect Effects 0.000 title claims description 7
- 238000000034 method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 210000005260 human cell Anatomy 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 27
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 22
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 22
- 239000002329 esterase inhibitor Substances 0.000 description 10
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 108010028774 Complement C1 Proteins 0.000 description 6
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 108010041397 CD4 Antigens Proteins 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 101000934958 Homo sapiens Complement C1s subcomponent Proteins 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 229940088950 c1 esterase inhibitor (human) Drugs 0.000 description 4
- 102000044507 human SERPING1 Human genes 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 102000004381 Complement C2 Human genes 0.000 description 2
- 108090000955 Complement C2 Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 206010019860 Hereditary angioedema Diseases 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000606113 Homo sapiens Tyrosine 3-monooxygenase Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
U
r/uu/u 1 1 2&/91 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT *t
.J
Application Number: Lodged: Invention Title: MODIFIED C1 ESTERASE INHIBITOR FOR BLOCKING THE INFECTIOUSNESS OF HIV The following statement Is a full description of this Invention, Including the best method of performing It known to us 1 MODIFIED C1 ESTERASE INHIBITOR FOR BLOCKING THE INFECTIOUSNESS OF HIV The invention relates to a modified C1 esterase inhibitor which can be employed for blocking the infectiousness of human immunodeficiency virus (HIV) in vivo or in vitro.
It is known that the removal of HIV from biological fluids, but especially from blood, blood plasma or blood serum, is an important prerequisite for their risk-free use for all sorts of medical purposes. Numerous processes have therefore also already been proposed using which removal of HIV from biological fluids should be achieved. Thus a process has been proposed in International Patent Application WO 97/07674 using which HIV can be removed from biological fluids or inactivated by treating them with certain ethylenimine oligomers. It is important in this case that other constituents of the blood, in particular the cellular constituents, especially the erythrocytes, are not damaged by a treatment of this type and the removal of HIV can be carried out in a simple manner and short time in order that sufficiently large amounts of purified blood can be obtained in an economically justifiable process.
We have already proposed a process to remove HIV from biological fluids adsorptively by means of filtration through a material impregnated with the C1 20 inhibitor in Australian granted patent No. 745851, the disclosure of which is incorporated herein by reference.
S"The C1 inhibitor, also called C1 esterase inhibitor, is a protein present in the blood and is the main inhibitor of the classical pathway of the complement system and of the contact system. The C1 inhibitor can inhibit the activated form of factor Xll and of kallikrein (Schapira M. et al., 1985, Complement 2: 111; Davis 1988, Ann Rev Immunol 6: 595; Sim R.B.
0 0 2 et al., 1979, FEBS Lett 97: 111; De Agostini A. et al., 1984, J Clin Invest 73: 1542; Pixley R.A. et al., 1985, J Biol Chem 260: 1723; Schapira M. et al., 1982, J Clin Invest 69: 462; Van der Graaf F. et al., 1983, J Clin Invest 71: 149; Harpel P.C. et al., 1975, J clin Invest 55: 593). The C1 inhibitor thus regulates the activities of two plasma cascades, namely the complement system and the contact system, by which biologically active peptides are produced. The C1 inhibitor is therefore also an important regulator of the inflammatory system. The C1 inhibitor moreover inhibits the activated factor XI (Meijers J.C.M. et al., 1988, Biochemistry 27: 959; Wuillemin W.A. et al., 1995, Blood 85: 1517). It follows from this that the C1 inhibitor can be considered as a coagulation inhibitor. The tissue plasminogen activator and plasmin are also inhibited to a certain extent by the C1 inhibitor, although that is not its main function (Harpel P.C. et al., 1975, J Clin Invest 55: 149; Booth N.A. et al., 1987, Blood 69: 1600).
The C1 inhibitor is obtained to a considerable extent from plasma by Spurification and utilized for clinical applications, in particular in the treatment of hereditary angioedema, a disorder which is caused by a genetically related lack of the C1 inhibitor. Moreover, it has already been described that by administration of the C1 inhibitor in systemic inflammations [International Patent Application WO 92/22320 (Genentech in severe burns, pancreatitis, bone marrow transplants, cytokine therapy and during use in a extracorporeal blood circulations [DE-A-4 227 762 (Behringwerke AG)] good therapeutic results were achieved.
The complete genomic and the cDNA which codes for the C1 inhibitor has already been cloned (Bock S.C. et al., 1986, Biochemistry 25: 4292; Carter P.E. et al., 1988, Eur J Biochem 173: 163). Various variants of the recombinant C1 inhibitor with amino acid mutations in the P1 and the P3 and/or P5 positions of the reactive center and variants which were isolated from patients with a hereditary angioedema have already been prepared recombinantly (Eldering E. et al., 1988, J Biol Chem 263: 11776; Eldering 3 E. et al., 1993, J Biol Chem 267: 7013; Eldering E. et al., 1993, J Clin Invest 91: 1035; US-Patent 5,622,930; Davis A.E. et al., 1992, Nature Genetics 1: 354; Eldering E. et al., 1995, J Biol Chem 270: 2579; Verpy et al., 1995, J Clin Invest 95: 350).
The C1 inhibitor belongs to the large family of serine proteinase inhibitors which are also called serpines (Travis J. et al., 1983, Ann Rev Biochem 52: 655; Carrel R.W. et al., 1985, Trends Bioch Sci 10: 20). On SDS polyacrylamide gels, the C1 inhibitor exhibits a molecular weight of approximately 105 KD. Its plasma concentration is approximately 270 mg/I (Schapira M et al., 1985, Complement 2: 111; Nuijens JH et al., 1989, J Clin Invest 84: 443). The C1 inhibitor is a protein whose plasma level can increase up to two-fold in uncomplicated infections and other inflammations (Kalter ES et al., 1985, J Infect Dis 151: 1019). The increased formation of the C1 inhibitor in inflammations probably serves to protect the body against the harmful effects of the intravascular activation S* of the complement system and of the contact system during the acute reactions.
The serpines react as inhibitors by formation of bimolecular complexes with the proteinase to be inhibited. In these complexes, the active center of S"the proteinase is bound by the active center of the serpine and thus inactive (Travis J. et al., 1983, Ann Rev Biochem 52: 655). The serpines react specifically with certain proteinases, this specificity being determined by the amino acid sequence of the reactive center.
The present invention starts from the observation that the infectiousness of HIV can be blocked by the administration of a C1 inhibitor.
As is known, the first step in an HIV infection consists in helper T lymphocytes (TH cells) of the immune system, which carry CD4 receptors on their surface, entering into an interaction with the surface proteins of HIV. Antibodies against CD4 block the HIV infection of TH cells in vitro. Even with an excess of free CD4 protein, the infection rate decreases in vitro. Both treatments admittedly block the infection, but do not destroy the virus. Similarly, the direct interaction between the surface proteins of HIV and the CD4 receptors of the TH cells can be suppressed according to the invention by binding of HIV to the C1 inhibitor.
The human C1 inhibitor, however, not only has a great affinity for the coat proteins of HIV, but also a great affinity for the surface proteins of lymphocytes. By means of the C1 inhibitor, a bridge-like connection can be produced between the HIV and the TH cell in the manner of a spacer. However, the infectiousness of HIV surprisingly still cannot be decreased by this. This can be achieved, however, if a modified C1 esterase inhibitor is employed which on the one hand has a high binding affinity for the coat proteins of HIV, but on the other hand does not bind to human cell membranes.
i. The term 'modified C1 esterase inhibitor' is to be understood in a functional sense o o 15 relative to the normal human C1 esterase inhibitor binding specificity. Whereas the human C1 esterase inhibitor binds to both HIV and human cell membranes, a modified C1 esterase inhibitor will bind to HIV but not to human cell membranes. Modified C1 esterase inhibitors include native non-human mammalian C1 esterase inhibitors which do not normally bind to human cells and native human C1 esterase inhibitors that are natural genetic variants or genetically engineered forms that will not bind to human cell membranes.
Modified C1 esterase inhibitors are available from different sources. Thus the C1 esterase inhibitors obtained from the blood of cattle or other mammals show no affinity a for human cell membranes, in particular not for the CD4 receptors of the human TH cells.
25 Their affinity for the surface proteins of HIV (gp 120 and gp41), however, can be compared with that of the human C1 esterase inhibitor. An animal C1 esterase inhibitor is therefore able to bind to the surface proteins of HIV, but prevents any contact of HIV with the human CD4 receptors, since the C1 inhibitor does not adhere to the surfaces of the TH cells.
There is, however, also the possibility of preparing modified variants of the human Cl inhibitor by a genetic engineering route. The exact amino acid sequence of the human C1 inhibitor and the DNA sequence which codes for this human C1 inhibitor have been described by Bock et al., Biochemistry 25: 4292-4301, 1986 and by Davis et al., PNAS 83: 3161-3165, 1986. Biologically active variants of the C1 esterase Inhibitor are known from the International Patent Application WO 91/06650 and are incorporated herein by reference. These variants can be prepared by recombinant expression processes, the DNA coding for the C1 esterase inhibitor having specific deletions, insertions or substitutions of nucleotides.
Fundamentally, all non-human C1 esterase inhibitors which do not bind to lymphocytes can be employed for blocking the infectiousness of HIV. These are either animal C1 esterase inhibitors isolated from natural material or animal C1 esterase inhibitors prepared recombinantly. Moreover, a recombinantly modified, human C1 esterase inhibitor whose binding ability to the CD4 receptors of the T-helper cells is abolished can block the infectiousness of HIV. For this, modifications of the amino acid sequence of the C1 inhibitor causing the binding to the CD4 receptor are necessary, which can be carried out by recombinant methods known per se and are described in particular in the International Patent Application WO 92/22320 and are incorporated herein by reference.
The abovementioned non-human C1 esterase inhibitors and recombinantly modified, human C1 esterase inhibitors are expediently administered parenterally and in an amount sufficient for the therapeutic action. In general, they are administered to the patient in a physiological saline solution, a Ringer's solution or another excipient suitable for injection purposes.
In Order to more clearly describe the subject invention, the following Example is provided.
Example The binding of Cl-inhibitor of human or bovine origin to HIV and human T-cells, respectively, was tested. HIV and a human T-cell line (Jurkat) were bound to a 96 well microtitre plate using standard methods. Cl-inhibitor serially diluted 1:2 in PBS/0.05% Tween 20 was added, incubated, washed, and blocked using standard methods. Bound C1- 25 inhibitor was detected using goat anti-human peroxidase conjugated antibody (Accurate Chemical Scientific Corporation, Westbury, NY, USA).
human C1-Inhibitor bovine C -Inhibitor C1-Inhibitor Jurkat HIV Jurkat
HIV
[conc] [Adsorption] [Adsorption] [Adsorption] [Adsorption] 1:10 0.98 0.63 0.21 0.52 1:20 0.72 0.56 '0.09 0.43 1:40 0.35 0.49 0.12 0.36 1:80 0.28 0.42 0.07 0.32 1:160 0.11 0.38 0.08 0.21 A nt.
I1 0 0.06 0.19 0.
1:640 0.07 0.10 0.09 u.vu 0.12
Claims (8)
1. A process for blocking the infectiousness of HIV, which comprises contacting HIV with a modified C1 esterase inhibitor as hereinbefore defined which on the one hand binds to HIV, but on the other hand not to human cell membranes.
2. A process according to claim 1 wherein the modified C1 esterase inhibitor is of non-human mammalian origin.
3. A process according to claim 1 wherein the modified C1 esterase inhibitor is of human origin.
4. A process according to claim 1 or 2 wherein the modified C1 esterase inhibitor is 10 selected from the group consisting of mouse, rat, bovine and chimpanzee origin. S*
5. A process according to claim 1 or 2 wherein the modified C1 esterase inhibitor is S* of bovine origin.
6. Use of a modified C1 esterase inhibitor as herein before defined which binds to HIV but not to human cell membranes for blocking the infectiousness of HIV in vivo or in vitro.
7. Use of a modified C1 esterase inhibitor as claimed in claim 6 in the form of a medicament for the in vivo treatment or prophylaxis of HIV AIDS.
8. A method of treatment or prophylaxis of HIV AIDS comprising administering to a patient, in need of such treatment or prophylaxis an efficacious amount of modified C1 esterase inhibitor substantially as hereinbefore defined. DATED this 5th day of September 2003 AVENTIS BEHRING GMBH WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P6173AU00 KJS/BJD/SLB
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19829014A DE19829014A1 (en) | 1998-06-30 | 1998-06-30 | Modified C1 esterase inhibitor to block the infectivity of HIV |
| DE19829014 | 1998-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3686599A AU3686599A (en) | 2000-01-13 |
| AU766767B2 true AU766767B2 (en) | 2003-10-23 |
Family
ID=7872412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU36865/99A Ceased AU766767B2 (en) | 1998-06-30 | 1999-06-29 | Modified C1 esterase inhibitor for blocking the infectiousness of HIV |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0969017A1 (en) |
| JP (1) | JP2000044599A (en) |
| KR (1) | KR20000006553A (en) |
| AU (1) | AU766767B2 (en) |
| CA (1) | CA2276564A1 (en) |
| DE (1) | DE19829014A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220557B2 (en) | 1997-04-24 | 2007-05-22 | Human Genome Sciences, Inc. | METH1 polynucleotides |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2535984A1 (en) * | 2003-08-19 | 2005-02-24 | Zlb Behring Gmbh | C1-inh as a drug for treating viruses pathogenic to humans |
| US9006477B2 (en) | 2011-07-07 | 2015-04-14 | Ihara Chemical Industry Co., Ltd. | Method for producing nitrobenzene compound |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601034B1 (en) * | 1986-07-03 | 1989-11-17 | Pasteur Institut | INHIBITOR OF THE ACTIVITY OF C1-ESTERASE PLASMATIC (C1-INHIBITOR) AND OF OTHER PROTEOLYTIC ENZYMES OF THE SERINE PROTEASE GROUP, PROCESS FOR PREPARING SAME, NUCLEIC ACIDS ENCODING THE SAME, DETECTION METHODS FOR DEFECTIVE CONDITIONS SAID INHIBITOR USING ANTIBODIES OR NUCLEOTIDE PROBES AND MEDICINES CONTAINING SAID SYNTHESIS INHIBITOR |
| WO1991006650A1 (en) * | 1989-10-27 | 1991-05-16 | Cetus Corporation | C1 inhibitor muteins and uses thereof |
| WO1992022320A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| PT716611E (en) * | 1993-09-01 | 2002-06-28 | Sanquin Bloedvoorziening | METHOD FOR REDUCING LYNX OF THE MYOCARDIO DURING A PAIN OF THE ACUTE MIOCARDIO |
-
1998
- 1998-06-30 DE DE19829014A patent/DE19829014A1/en not_active Ceased
-
1999
- 1999-06-18 EP EP99111763A patent/EP0969017A1/en not_active Withdrawn
- 1999-06-29 JP JP11182805A patent/JP2000044599A/en active Pending
- 1999-06-29 AU AU36865/99A patent/AU766767B2/en not_active Ceased
- 1999-06-29 CA CA002276564A patent/CA2276564A1/en not_active Abandoned
- 1999-06-29 KR KR1019990025166A patent/KR20000006553A/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220557B2 (en) | 1997-04-24 | 2007-05-22 | Human Genome Sciences, Inc. | METH1 polynucleotides |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0969017A1 (en) | 2000-01-05 |
| JP2000044599A (en) | 2000-02-15 |
| DE19829014A1 (en) | 2000-01-05 |
| KR20000006553A (en) | 2000-01-25 |
| CA2276564A1 (en) | 1999-12-30 |
| AU3686599A (en) | 2000-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0719154B1 (en) | Activated factor viii as a therapeutic agent and method of treating factor viii deficiency | |
| EP0638088B1 (en) | Hybrid human/porcine factor viii | |
| US6103693A (en) | Method for isolation of highly pure von willebrand factor | |
| RU2166326C2 (en) | Combination of thrombolytically active proteins and anticoagulants | |
| EP0352903B1 (en) | Bovine factor Xa inhibiting factor and pharmaceutical compositions containing the same | |
| EP1560590A2 (en) | Synthetic complementary peptides and ophthalmologic uses thereof | |
| EP0317053B1 (en) | Trigramin- a platelet aggregation inhibiting polypeptide | |
| Maraganore | Thrombin, thrombin inhibitors, and the arterial thrombotic process | |
| JPH09221432A (en) | Medicine preparation containing von willebrand's factor | |
| NO324064B1 (en) | Pharmaceutical composition comprising vWF propeptide and method of preparation and use thereof | |
| CA2131153C (en) | Peptides stimulating cytotoxic lymphocytes response to hiv-i gp 160 | |
| US6017880A (en) | Inhibition of retrovirus infection | |
| AU766767B2 (en) | Modified C1 esterase inhibitor for blocking the infectiousness of HIV | |
| EP0301458A2 (en) | Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses | |
| AU745851B2 (en) | Process for separating HIV from a fluid | |
| US5714461A (en) | Medicinal compositions for the improvement of blood coagulation comprising TCF-II | |
| US6869925B1 (en) | Inhibition of retrovirus infection | |
| US20130142779A1 (en) | Treatment of Hi-Virus infections with oxidised blood proteins | |
| WO1996013160A1 (en) | Use of urokinase-type plasminogen activators to inhibit hiv infectivity | |
| US5204321A (en) | Heparin neutralization with platelet factor 4 | |
| US6103691A (en) | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins | |
| US20040152635A1 (en) | Modified C1 esterase inhibitor for blocking the infectiousness of HIV | |
| WO1993007890A1 (en) | Treatment of haemophilia | |
| Damas | The novel rat kininogen, T-kininogen. A pro-inflammatory factor or a thiostatin? | |
| JPH10504310A (en) | How to treat a patient with a biologically active compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: AVENTIS BEHRING GMBH Free format text: FORMER NAME: CENTEON PHARMA GMBH |
|
| FGA | Letters patent sealed or granted (standard patent) |